Welcome to the UPF Digital Repository
Browsing Online Master in Health Economics and Pharmacoeconomics by Issue Date
- Home
- →
- Treballs d'estudiants
- →
- Treballs de la UPF Barcelona School of Management
- →
- Online Master in Health Economics and Pharmacoeconomics
- →
- Browsing Online Master in Health Economics and Pharmacoeconomics by Issue Date
JavaScript is disabled for your browser. Some features of this site may not work without it.
Browsing Online Master in Health Economics and Pharmacoeconomics by Issue Date
Now showing items 1-13 of 13
-
(2019)Background: In 2001, 46 African Union nations signed the Abuja Declaration, committing 15 percent of their public expenditures to health. Objectives: In this paper, I was motivated to determine if government spending on ...
-
(2019)Background: Guidelines recommend that Cancer-associated thrombosis (CAT) should be treated with low-molecular weight heparins (LMWH), which prevent more effectively the recurrence of Venous Thrombo-Embolism (VTE) than ...
-
(2020)Continued cancer research allows for the development of novel and potentially superior treatments and management approaches. The recent identification of the role of the immune system in cancer has led to the development ...
-
(2020)Patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) have a poor prognosis with conventional therapies. In the summer of 2018, the European Medicines Agency approved tisagenlecleucel (tisa-cel, ...
-
(2021)There is a growing interest in measuring youth preferences for decision making. The EQ-5D-Y-3L is generic preference-based instrument developed by the EuroQol Group that is appropriate for children and adolescents. Recent ...
-
(2021)Background: Insulin replacement therapy is the cornerstone for the treatment of type 1 and 2 diabetes mellitus. Two of the most used methods are continuous subcutaneous insulin infusion and multiple daily injections. This ...
-
(2021)Depression is an illness that has a strong social and economic impact, and that has seen its prevalence increased during the COVID-19 pandemic. As with many sectors of healthcare, the increased costs of treatment and the ...
-
(2021)Background: Namibia is only notifying 62% of the estimated TB cases. Xpert MTB/RIF (Xpert) is considered the gold standard for tuberculosis (TB) diagnosis. The urine lipoarabinomannan (LF-LAM) assay has been recommended ...
-
(2021)A rare disease is one that affects less than 1 in 2,000 in general population, and they are often chronic and life-threatening. Due to the high cost to develop and small market for orphan drugs, historically manufacturers ...
-
(2021)The purpose of this study is to conclude as to whether it is cost-effective to introduce genotyping in the Norwegian clinical practice in the case of acute coronary syndrome, as a guide of pharmacotherapy decision making ...
-
(2022)Background. Cardiovascular diseases have a significant economic burden on healthcare systems. Effective treatments for hypercholesterolemia are available, with statins being currently the standard of care. A ...
-
(2022)Background: Despite progress in recent years, generic drugs markets are not developing its full potential, particularly in countries with more intense price regulation. Tendering is an alternative and indirect price setting ...
Now showing items 1-13 of 13
